- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Differential susceptibility.
Displaying page 1 of 1.
| EudraCT Number: 2014-000206-36 | Sponsor Protocol Number: DOPA1 | Start Date*: 2014-10-27 |
| Sponsor Name: | ||
| Full Title: DRD4 genotype as a moderator of L-Dopa intervention effects on parent-related neurocognitive processes, behaviors, and attitudes: A micro-trial of differential susceptibility to pharmacological int... | ||
| Medical condition: There are no medical conditions or diseases under investigation. | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-001521-25 | Sponsor Protocol Number: NEOMERO-2 | Start Date*: 2011-12-15 | |||||||||||
| Sponsor Name:FONDAZIONE PENTA ONLUS | |||||||||||||
| Full Title: Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: a European multicenter phase II trial | |||||||||||||
| Medical condition: Bacterial meningitis in children up to 90 days of age | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed) NL (Completed) GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-006032-22 | Sponsor Protocol Number: 41829447 (ISRCTN No) | Start Date*: 2007-04-04 |
| Sponsor Name:University of Manchester [...] | ||
| Full Title: TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis | ||
| Medical condition: Rheumatoid arthritis is associated with increased mortality from cardiovascular disease (CVD). Statins have a proven effect in reducing CVD events in at-risk populations, mostly due to their chole... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-001515-31 | Sponsor Protocol Number: NEOMERO-1 | Start Date*: 2011-08-25 | |||||||||||
| Sponsor Name:FONDAZIONE PENTA ONLUS | |||||||||||||
| Full Title: EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL | |||||||||||||
| Medical condition: late onset sepsis in the neonate and infant up to 90 days of age | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-004399-38 | Sponsor Protocol Number: CRx-102-007E | Start Date*: 2008-04-18 | |||||||||||
| Sponsor Name:CombinatoRx, Incorporated | |||||||||||||
| Full Title: A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, 1-YEAR EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFECTIVENESS OF CRx-102 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS | |||||||||||||
| Medical condition: RHEUMATOID ARTHRITIS (RA) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005772-16 | Sponsor Protocol Number: HEH-SF-01 | Start Date*: 2016-06-22 | ||||||||||||||||
| Sponsor Name:Department of Surgery, Herlev Hospital | ||||||||||||||||||
| Full Title: The safety and pharmacokinetics of intraperitoneal administration of granulocyte-macrophage colony-stimulating factor, fosfomycin, and metronidazole in patients undergoing appendectomy for uncompli... | ||||||||||||||||||
| Medical condition: We intend to investigate the safety of treating secondary infectious peritonitis due to uncomplicated appendicitis with intraperitoneally administered fosfomycin, metronidazole and GM-CSF. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-011268-13 | Sponsor Protocol Number: RN08RH469 | Start Date*: 2009-12-31 | |||||||||||
| Sponsor Name:NHS Greater Glasgow and Clyde [...] | |||||||||||||
| Full Title: Optimal management of rheumatoid arthritis patients who require biologic therapy (ORBIT study) | |||||||||||||
| Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-004038-12 | Sponsor Protocol Number: 19-01 | Start Date*: 2021-12-10 |
| Sponsor Name:CENTRE HOSPITALIER ANNECY GENEVOIS | ||
| Full Title: Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheter-related bloodstream infections due to Staphylococcus aureus | ||
| Medical condition: Staphylococcus aureus catheter bloodstream infection | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-006082-11 | Sponsor Protocol Number: ADG20-TRMT-001 | Start Date*: 2021-06-02 | |||||||||||
| Sponsor Name:Adagio Therapeutics Inc. | |||||||||||||
| Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Prematurely Ended) RO (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-005036-26 | Sponsor Protocol Number: FXT-05 | Start Date*: 2011-11-29 | ||||||||||||||||||||||||||
| Sponsor Name:Funxional Therapeutics Ltd | ||||||||||||||||||||||||||||
| Full Title: An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease | ||||||||||||||||||||||||||||
| Medical condition: Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2006-004834-33 | Sponsor Protocol Number: ROB 803-09-002 | Start Date*: 2007-07-05 | |||||||||||
| Sponsor Name:OxyPharma AB | |||||||||||||
| Full Title: A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 when Adde... | |||||||||||||
| Medical condition: Rheumatiod Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Completed) LV (Completed) GB (Completed) BE (Completed) BG (Completed) PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005163-16 | Sponsor Protocol Number: U1111-1171-4970 | Start Date*: 2016-05-30 | ||||||||||||||||
| Sponsor Name:The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark | ||||||||||||||||||
| Full Title: Effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis. A randomised, double blind, placebo-controlled, parallel group, single-centre trial | ||||||||||||||||||
| Medical condition: Adult (≥ 18 years of age) overweight or obese patients (BMI ≥ 27 kg/m2 ) above 18 years of age with knee osteoarthritis (OA) defined by clinical diagnosis of knee OA according to the American Colle... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.